Annual Drug Patent Expiration for NAROPIN
Naropin is a drug marketed by Fresenius Kabi Usa and is included in one NDA. It is available from three suppliers. There are four patents protecting this drug and three Paragraph IV challenges.
Drug patent litigation for NAROPIN.
This drug has sixty-six patent family members in twenty countries.
The generic ingredient in NAROPIN is ropivacaine hydrochloride. Three suppliers are registered for this compound. Additional details are available on the ropivacaine hydrochloride profile page.
For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs, contact admin@DrugPatentWatch.com or visit www.DrugPatentWatch.com
Copyright © DrugPatentWatch. Originally published in Recently expired patent for the drug Fresenius Kabi NAROPIN